Keywords
BTA stat
NMP22
Survivin
Urothelial carcinoma
Submitted : 2025-03-03
Accepted : 2025-03-18
Published : 2025-04-02
Abstract
Objective: To explore the diagnostic value of combined detection of bladder tumor antigen (BTA), bladder tumor antigen-associated test (BTA stat), nuclear matrix protein 22 (NMP22), and survivin in urothelial carcinoma. Methods: Sixty patients with urothelial carcinoma admitted from January 2024 to January 2025 were selected as the observation group for this study, and 60 healthy individuals were selected as the control group. BTA, BTA stat, NMP22, and survivin tests were performed on both groups, respectively. The test results were analyzed to evaluate the diagnostic value of combined detection. Results: The levels of BTA, BTA stat, NMP22, and survivin in the observation group were higher than those in the control group (P < 0.05). The specificity, sensitivity, and accuracy of combined detection of BTA, BTA stat, NMP22, and survivin were higher than those of single detection methods (P < 0.05). There were significant differences in the positive rates of BTA, BTA stat, NMP22, and survivin among patients with different tumor diameters, tumor numbers, pathological grades, clinical stages, and lymph node metastasis status (P < 0.05). Conclusion: In the diagnosis of urothelial carcinoma, the combined detection of BTA, BTA stat, NMP22, and survivin has high diagnostic value and can be promoted and applied in clinical diagnosis.
References
He H, Li L, Feng A, et al., 2020, Global Incidence and Mortality of Bladder Cancer from 1990 to 2017. Chinese Journal of Evidence-Based Medicine, 20(11): 1257–1265.
Lin T, Lin H, Wu S, 2024, Current Status and Prospects of Non-invasive Diagnosis of Bladder Cancer. Journal of Clinical Urology, 39(12): 1037–1041.
Mao T, Zhang W, Luo J, 2021, Expression and Significance of Survivin in Circulating Tumor Cells (CTCs) in Peripheral Blood of Patients with Bladder Cancer. Hainan Medical Journal, 32(22): 2890–2893.
Siegel RL, Miller KD, Jemal A, 2019, Cancer statistics. CA Cancer J Clin, 69(1): 7–34.
Zhang Y, Fan J, 2024, Research Progress of Volatile Organic Compounds in Urine in Non-invasive Diagnosis Technology for Bladder Cancer. Journal of Clinical Urology, 39(12): 1067–1070 + 1075.
Zuo M, Li W, Wang Z, et al., 2023, Predictive Value of Fibroblast Growth Factor 19 Combined with Fibroblast Growth Factor 21 Detection in Patients with Urothelial Carcinoma. China Modern Medicine, 30(15): 69–73 + 197.
Wang X, Zhang Y, Zhang S, et al., 2024, Diagnostic Value of Bladder Tumor Antigen, Urinary Nuclear Matrix Protein 22, and Cytokeratin-19 for Bladder Cancer. Cancer Progress, 22(15): 1667–1670.
Yang L, Xu H, Yang H, et al., 2024, Study on the Diagnostic Value of Preoperative Quantitative Detection of Urinary BTA and NMP22 for Bladder Cancer. Lingnan Modern Clinical Surgery, 24(01): 37–41.
Zhu Y, Li Y, Song G, 2020, Value of Urine NMP22, OPN, and BTA Detection in the Diagnosis and Prognostic Evaluation of Bladder Urothelial Carcinoma. Minimally Invasive Urology Journal, 9(03): 203–207.
Xiong X, Xiong B, Yao F, 2020, Application Value of CYFRA21-1 and BTA stat Detection in the Diagnosis of Bladder Cancer. Medical Information, 33(22): 104–106.
Huang Y, Liu Z, Dong G, et al., 2024, Diagnostic Value of Urine Basal Cell Fluorescence in Situ Hybridization Detection for Bladder Urothelial Carcinoma. Modern Urology Journal, 29(06): 505–509.
Huang L, Ben L, Yu J, et al., 2020, Relationship Between Blood miR-21 and Urine NMP-22 Expression and Surgical Prognosis of Patients with Bladder Urothelial Carcinoma. Chinese Journal of Health Care Medicine, 22(06): 617–620.
Zhang R, Wang Q, Zhu W, 2023, Expression Levels of Survivin, Cyclin D1, and hMSH2 in Bladder Urothelial Carcinoma Tissues and Their Value in Predicting Postoperative Recurrence. Chinese Medical Engineering, 31(06): 122–125.
Luo C, Ke M, Han Z, 2020, Expression and Clinical Significance of Survivin Gene in Bladder Urothelial Carcinoma Tissues. Modern Chinese Doctor, 58(08): 15–18.
Dong T, Chen L, Liu X, et al., 2021, Research Progress of Bladder Cancer Biomarkers in Urine. Medical Review, 27(12): 2365–2370.
Hu Y, Deng X, Zhou A, et al., 2021, Relationship Between the Expression of CRMP2, NUSAP1, and hMSH2 in Bladder Urothelial Carcinoma Tissues and Clinicopathological Parameters and Prognosis. Progress in Modern Biomedicine, 21(1): 178–183.
Wang L, Ma L, Ge Y, et al., 2021, Expression and Influencing Factors of Bladder Tumor Antigen in Urine of Patients with Bladder Cancer. Community Medical Journal, 19(02): 81–83 + 87.
Wang H, Shi H, 2024, Clinical Application Value of NMP22/Cr Value in the Diagnosis of Bladder Cancer in Primary Medical Units. Journal of Ningxia Medical University, 46(11): 1141–1145.
Xu L, Zhu D, Yuan C, 2020, Expression and Clinical Correlation of Survivin in Exfoliated Cells in Urine of Patients with Bladder Cancer. Chinese Journal of Laboratory Diagnosis, 24(02): 316–319.
Huang X, Hu D, Chen X, et al., 2023, Research Progress on the Application of Urinary Markers in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma. Chinese Medical Innovation, 20(25): 181–184.